UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24), p.9330-9336

2009

Volltextzugriff (PDF)

Clinical development of HER3-targeting monoclonal antibodies: Perils and progress

Cancer treatment reviews, 2018-07, Vol.68, p.111-123

2018

Volltextzugriff (PDF)

Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts

Oncogene, 2021-04, Vol.40 (15), p.2651-2666

2021

Volltextzugriff (PDF)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

PloS one, 2017-05, Vol.12 (5), p.e0177331-e0177331

2017

Volltextzugriff (PDF)

Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions

Communications biology, 2018-04, Vol.1 (1), p.28-28, Article 28

2018

Volltextzugriff (PDF)

Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy

Molecular cancer therapeutics, 2018-07, Vol.17 (7), p.1464-1474

2018

Volltextzugriff (PDF)

Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy

Clinical cancer research, 2005-07, Vol.11 (14), p.5300-5309

2005

Volltextzugriff (PDF)

FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis

Cancer research (Chicago, Ill.), 2003-11, Vol.63 (21), p.7436-7442

2003

Volltextzugriff (PDF)

Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies

Clinical cancer research, 2011-07, Vol.17 (13), p.4451-4461

2011

Volltextzugriff (PDF)

Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization

Molecular cancer therapeutics, 2009-07, Vol.8 (7), p.1885-1892

2009

Volltextzugriff (PDF)

Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity

Molecular cancer research, 2009-09, Vol.7 (9), p.1563-1571

2009

Volltextzugriff (PDF)

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

ESMO open, 2019-07, Vol.4 (4), p.e000532-e000532, Article e000532

2019

Volltextzugriff (PDF)

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

Molecular cancer therapeutics, 2007-01, Vol.6 (1), p.93-100

2007

Volltextzugriff (PDF)

Molecular determinants of trastuzumab efficacy: What is their clinical relevance?

Cancer treatment reviews, 2013-12, Vol.39 (8), p.925-934

2013

Volltextzugriff (PDF)

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab

Molecular oncology, 2013-06, Vol.7 (3), p.580-594

2013

Volltextzugriff (PDF)

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

The New England journal of medicine, 2017-07, Vol.377 (2), p.122-131

2017

Volltextzugriff (PDF)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab

Pharmaceuticals (Basel, Switzerland), 2012-06, Vol.5 (7), p.674-689

2012

Volltextzugriff (PDF)

Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

Clinical cancer research, 2021-02, Vol.27 (3), p.807-818

2021

Volltextzugriff (PDF)

Disentangling ERBB Signaling in Breast Cancer Subtypes-A Model-Based Analysis

Cancers, 2022-05, Vol.14 (10), p.2379

2022

Volltextzugriff (PDF)

Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3

Carcinogenesis (New York), 2013-09, Vol.34 (9), p.2031-2038

2013

Volltextzugriff (PDF)

Direct estrogen receptor

PloS one, 2017-05, Vol.12 (5), p.e0177331

2017

Volltextzugriff (PDF)

Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy

Clinical cancer research, 2005-05, Vol.11 (9), p.3503-3513

2005

Volltextzugriff (PDF)

Antikörper - neue Krebsmedikamente. Gezielt wirksame Biomedizin

Chemie in unserer Zeit, 2009-10, Vol.43 (5), p.328-338

2009

Volltextzugriff (PDF)

Abstract 537: Is interrupting IGF1R signaling enough to overcome resistance to trastuzumab in HER2+ breast cancer models?

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.537-537

2013

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(37)

Sprache

Englisch
(36)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

Clinical development of HER3-targeting monoclonal antibodies: Perils and progress

Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions

Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy

Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy

FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis

Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies

Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization

Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

Molecular determinants of trastuzumab efficacy: What is their clinical relevance?

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab

Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

Disentangling ERBB Signaling in Breast Cancer Subtypes-A Model-Based Analysis

Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3

Direct estrogen receptor

Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy

Antikörper - neue Krebsmedikamente. Gezielt wirksame Biomedizin

Abstract 537: Is interrupting IGF1R signaling enough to overcome resistance to trastuzumab in HER2+ breast cancer models?

Suchergebnisse filtern